89bio Statistics
Share Statistics
89bio has 117.58M shares outstanding. The number of shares has increased by 40.31% in one year.
| Shares Outstanding | 117.58M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 7.65% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 112.42M |
| Failed to Deliver (FTD) Shares | 134.29K |
| FTD / Avg. Volume | 17.18% |
Short Selling Information
The latest short interest is 5.38M, so 4.58% of the outstanding shares have been sold short.
| Short Interest | 5.38M |
| Short % of Shares Out | 4.58% |
| Short % of Float | 4.79% |
| Short Ratio (days to cover) | 10.28 |
Valuation Ratios
The PE ratio is -5.59 and the forward PE ratio is -3.15.
| PE Ratio | -5.59 |
| Forward PE | -3.15 |
| PS Ratio | 0 |
| Forward PS | 362.2 |
| PB Ratio | 1.48 |
| P/FCF Ratio | -6.15 |
| PEG Ratio | n/a |
Enterprise Valuation
89bio Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 20.04, with a Debt / Equity ratio of 0.05.
| Current Ratio | 20.04 |
| Quick Ratio | 20.04 |
| Debt / Equity | 0.05 |
| Total Debt / Capitalization | 4.5 |
| Cash Flow / Debt | -5.11 |
| Interest Coverage | -42.17 |
Financial Efficiency
Return on equity (ROE) is -0.27% and return on capital (ROIC) is -27.59%.
| Return on Equity (ROE) | -0.27% |
| Return on Assets (ROA) | -0.24% |
| Return on Capital (ROIC) | -27.59% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -2.03M |
| Employee Count | 70 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 3.87M |
| Effective Tax Rate | -0.03 |
Stock Price Statistics
The stock price has increased by -27.36% in the last 52 weeks. The beta is 0.98, so 89bio 's price volatility has been higher than the market average.
| Beta | 0.98 |
| 52-Week Price Change | -27.36% |
| 50-Day Moving Average | 8.38 |
| 200-Day Moving Average | 8.96 |
| Relative Strength Index (RSI) | 41.27 |
| Average Volume (20 Days) | 781.84K |
Income Statement
In the last 12 months, 89bio had revenue of $0 and earned -$142.19M in profits. Earnings per share was $-2.
| Revenue | 0 |
| Gross Profit | -273.00K |
| Operating Income | -151.20M |
| Net Income | -142.19M |
| EBITDA | -134.46M |
| EBIT | - |
| Earnings Per Share (EPS) | -2 |
Balance Sheet
The company has $316.16M in cash and $27.11M in debt, giving a net cash position of $289.05M.
| Cash & Cash Equivalents | 316.16M |
| Total Debt | 27.11M |
| Net Cash | 289.05M |
| Retained Earnings | -457.43M |
| Total Assets | 458.30M |
| Working Capital | 417.07M |
Cash Flow
In the last 12 months, operating cash flow was -$129.19M and capital expenditures -$4.00K, giving a free cash flow of -$129.19M.
| Operating Cash Flow | -129.19M |
| Capital Expenditures | -4.00K |
| Free Cash Flow | -129.19M |
| FCF Per Share | -1.82 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
ETNB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -25.97% |
| FCF Yield | -14.27% |
Analyst Forecast
The average price target for ETNB is $29.5, which is 283.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $29.5 |
| Price Target Difference | 283.1% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | 3.99 |
| Piotroski F-Score | 3 |